Skip to main content

Table 2 Efficacy of third-generation EGFR-TKIs

From: Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases

Short-term efficacy

  
 

PR

138(71.1%)

 

SD

40(20.6%)

 

PD

16(8.2%)

ORR

71.1%

DCR

91.8%

 

iCR

34(17.5%)

 

iPR

106(54.6%)

 

iSD

31(15.9%)

 

iPD

23(11.8%)

iORR

72.2%

iDCR

88.2%

miPFS

15.67months (7.88–20.26, IQR)

  1. Abbreviation: IQR Interquartile range
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us